At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
conventionally fractionated full dose re-irradiation +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer
In Brief
A Phase 2 clinical trial evaluating conventionally fractionated full dose re-irradiation and hypofractionated palliative re-irradiation for Head and Neck Cancer. Completed, enrolled 87 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the tumor control and the side effects of using proton therapy for head and neck cancer that has come back.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedJul 2017
Primary CompletionMar 2026
TodayJul 2026
First PostedJul 14, 2017
Enrollment StartJul 10, 2017
Primary CompletionMar 18, 2026
TodayJul 1, 2026
Enrollment to primary: 8.7 yearsPosted 9.0 years ago
Interventions
conventionally fractionated full dose re-irradiationradiation
re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
hypofractionated palliative re-irradiationradiation
course or a hypofractionated palliative re-irradiation "Quad Shot" course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles).